It is well-known that hPL is one of the most important enzymes responsible for the digestion of dietary lipid (such as triacylglycerols) in the intestinal tract (14, 49), while hPL inhibitor therapy has been validated as an efficacious and cost-effective way for preventing and treating obesity and overweight. The gene discussed is LGALS1; the disease is obesity due to melanocortin 4 receptor deficiency.